ISR News 2.51 08/22/2014 05:18:32 Isoray Inc (ISR)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Isoray Inc (ISR) 2.51 $ISR

Top Swing Trade Ideas for Thursday, Aug. 21: Alcoa, Sodastream, More
at The Street - Thu Aug 21, 9:45AM CDT
Alcoa, SodaStream and IsoRay are our big swing trades for Thursday. So how should investors buy and sell?

Hot Stock: IsoRay, Shares Gain 10.7% (ISR)
Comtex SmarTrend(R) - Tue Aug 05, 10:08AM CDT
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 10.7% to $2.64 on 1.0x average daily volume. IsoRay has traded 2.6 million shares thus far today, vs. average volume of 2.5 million shares per day. The stock has outperformed the Dow (10.5% to the Dow's -0.4%) and outperformed the S&P 500 (10.5% to the S&P's -0.4%) during today's trading.

IsoRay's Cesium-131 Isotope Produces Excellent Results in Treating Metastatic Brain Cancer as Published in the Journal of Neurosurgery
Marketwire - Tue Aug 05, 7:32AM CDT
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the publication of the first major peer reviewed study showing superior results using IsoRay's Cesium-131 seeds in the treatment of metastatic brain cancer.

Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences
PR Newswire - Thu Jul 31, 7:40AM CDT
On Wednesday, July 30, 2014, the NASDAQ Composite ended at 4,462.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.19% lower at 16,880.36, and the S&P 500 closed at 1,970.07, up 0.01%. During the session five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 718.94, up 0.36%, and the index has advanced 2.05% in the last one month. Investor-Edge has initiated coverage on the following equities: IsoRay Inc. (NYSE MKT: ISR), Neurocrine Biosciences Inc. (NASDAQ: NBIX), OPKO Health Inc. (NYSE: OPK), Orexigen Therapeutics Inc. (NASDAQ: OREX), and Gilead Sciences Inc. (NASDAQ: GILD). Free research on these five companies can be accessed at:

Why IsoRay (ISR) Stock Is Spiking Today
at The Street - Mon Jul 14, 10:41AM CDT
IsoRay (ISR) shares are climbing after the company's Cesium-131 internal radiation seeds were used in the world's first successful stereotactic brain implant surgery.

IsoRay Makes First Cesium-131 Delivery for Treatment of an Inoperable Brain Cancer Afflicting a Young Child in Peru
Marketwire - Mon Jul 14, 7:30AM CDT
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the first Cesium-131 seed shipment to Peru for the treatment of a Glioma brain tumor located near the brainstem.

IsoRay Announces Its Addition to the Russell Microcap Index
Marketwire - Mon Jun 30, 7:45AM CDT
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for cancers of the brain, lung, head and neck, prostate and gynecologic ("gyn" , today announced that it has been added to the Russell Microcap Index.

A Beaten-Down Biotech Stock Gearing Up for a Big Squeeze Higher
at The Street - Tue Jun 24, 1:22PM CDT
The shorts are betting against this biotech stock, but its technical chart is telling a different story.

Traders Get Bullish on Shares of IsoRay, Shares Up 15.2% (ISR)
Comtex SmarTrend(R) - Tue Jun 24, 10:09AM CDT
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 15.2% to $3.08 on 5.1x average daily volume. IsoRay has traded 9.9 million shares thus far today, vs. average volume of 1.9 million shares per day. The stock has outperformed the Dow (15.2% to the Dow's 0.1%) and outperformed the S&P 500 (15.2% to the S&P's 0.3%) during today's trading.

Why IsoRay (ISR) Stock Is Surging Today
at The Street - Tue Jun 24, 9:38AM CDT
IsoRay (ISR) surged Tuesday after the company announced the world's first liquid cesium-131 treatment for metastatic brain cancer.

IsoRay Announces World's First Liquid Cesium-131 (Cesitrex(R)) Treatment for Metastatic Brain Cancer Utilizing the GliaSite(R) Radiation Therapy Balloon Catheter System
Marketwire - Tue Jun 24, 7:45AM CDT
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced another milestone -- the treatment of a brain tumor that had metastasized from esophageal cancer utilizing IsoRay's liquid Cesium-131 (Cesitrex(R)) which recently was FDA cleared for internal radiation therapy.

Health Care Sector Stocks Technical Analysis -- Research on United Therapeutics, IsoRay, Bruker, and Affymetrix
PR Newswire - Mon Jun 23, 6:50AM CDT
On Friday, June 20, 2014, the NASDAQ Composite ended at 4,368.04, up 0.20%, the Dow Jones Industrial Average finished the session at 16,947.08, up 0.15% and the S&P 500 closed at 1,962.87, up 0.17%. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.84% higher at 702.66, and the index has advanced 3.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: United Therapeutics Corp. (NASDAQ: UTHR), IsoRay Inc. (NYSE MKT: ISR), Bruker Corp. (NASDAQ: BRKR) and Affymetrix Inc. (NASDAQ: AFFX). Free technical research on UTHR, ISR, BRKR and AFFX can be downloaded upon signing up at:

IsoRay Announces New Russian and Peruvian International Distributor Agreements for the Sale of IsoRay's Full Line of Products
Marketwire - Fri Jun 20, 7:45AM CDT
IsoRay, Inc. (NYSE MKT: ISR) (http://www.isoray.com/), announced today that it has entered into two (2) international distribution agreements: the first with MedikorPharma-Ural LLC for the Russian market and the other with Surgicorp SRL for the Peruvian market. IsoRay is a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer, prostate cancer and gynecologic ("gyn" cancer.

Hot Stock: IsoRay, Shares Gain 22.3% (ISR)
Comtex SmarTrend(R) - Tue Apr 01, 10:10AM CDT
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 22.3% to $2.69 on 1.4x average daily volume. IsoRay has traded 16.0 million shares thus far today, vs. average volume of 11.1 million shares per day. The stock has outperformed the Dow (22.3% to the Dow's 0.4%) and outperformed the S&P 500 (22.3% to the S&P's 0.4%) during today's trading.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 120

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 117

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
Segway Powersports Ventures into Baja 1000: Ambitions Run High

Updated Category News Views 20

They're gunning for glory in the sands of Baja, folks—Segway Powersports is about to rev up the excitement with its Baja 1000 debut. Never heard before in this legendary race's chronicles, Segway aims to shake up the game with their two brawny Super Villain UTVs. These aren't your run-of-the-pavement ride-ons; they're built for the rough stuff—and if there's a stage...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 439

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Cars.com Inducement Awards: New CPO Earns Stock Boost

Updated Category News Views 57

Revving Up With Incentives: A Strategic Move by Cars.com Ever seen a stock maneuver that feels more like a chess play than a plain deal? On November 5, 2026, Cars.com (NYSE: CARS) fired up quite a strategic engine. They handed out a heap of restricted stock units—373,345 to be precise—to Mausam Bhatt, freshly minted as their Chief Product Officer. This isn't just your...

Continue Reading
Tencent Cloud's Edge Platform Shines in New Gartner Report

Updated Category News Views 24

The Breakthrough in Edge Computing Everyone's talking about cloud this and cloud that, but Tencent Cloud is taking things a notch further with its EdgeOne platform. It's not just about storing your files in the sky; it's about having the fastest, most secure delivery possible. Gartner's latest report puts these guys right at the top in their Magic Quadrant for Edge...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 322

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 417

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 302

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 147

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading

Top 5 Most Recently Viewed Articles

Verint's Investor Day: Unveiling Key Innovations in CX Automation

Updated Category News Views 254

Exciting Updates from Verint's Investor Day Event Verint® (Nasdaq: VRNT), known as The CX Automation Company™, has recently held its much-anticipated Investor Day, highlighting significant advancements and outlined strategies aimed at shaping the future of customer experience (CX). The event kicked off with CEO Dan Bodner expressing enthusiasm about discussing the...

Continue Reading
Tri Pointe Homes, Inc. Delivers Strong Q3 2025 Performance

Updated Category News Views 255

Tri Pointe Homes Reports Outstanding Third Quarter Performance Tri Pointe Homes, Inc. (NYSE: TPH), a leading homebuilder in America, has unveiled strong results for the third quarter of 2025, highlighting significant achievements in home deliveries and financial performance. Key Highlights of Q3 2025 The company has reported a total of 1,217 new home deliveries during...

Continue Reading
Main Street Capital Q3 2024 Results Showcase Strong Growth

Updated Category News Views 144

Main Street Capital Reports Impressive Financial Results Main Street Capital Corporation (NYSE: MAIN) is excited to share its financial results for the third quarter of 2024. With solid performance reflected in higher net investment income and a robust capital position, the company demonstrates its commitment to delivering value to shareholders. Highlights from Q3 2024...

Continue Reading
Rathbones Group Plc's Significant Position in Warpaint London

Updated Category News Views 194

Key Disclosure of Rathbones Group Plc In the financial landscape, transparency is of utmost importance, especially when significant interests in securities come to light. Rathbones Group Plc has provided a crucial disclosure as they maintain an interest in relevant securities of Warpaint London Plc, representing over 1% of their shares. This type of disclosure aligns with...

Continue Reading
Anticipated Surge in Electric Trucks Market to $20.32 Billion

Updated Category News Views 149

Overview of the Electric Trucks Market Growth The global electric trucks market is projected to witness significant growth, with estimates indicating an increase of USD 20.32 billion from recent years through to 2028. This growth trajectory shows an impressive compound annual growth rate (CAGR) of approximately 35.44%. The rising demand for fuel-efficient and low-emission...

Continue Reading